Carbinoxamine Maleate
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Carbinoxamine Maleate
- Generic name
- CARBINOXAMINE MALEATE
- Manufacturer
- Genus Lifesciences Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 9d11b197-cfdc-4b9b-9935-2920ccb6e522
- SPL ID
- 12a85f25-d18a-4408-8c66-4e0182287026
- Version
- 6
- Effective date
- 2024-03-06
- Source export date
- 2026-10-12
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/edd23646015c9adc800cdbe2b778398a2d2b70e90dce5721ef2b191499a0397f/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:54:20
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 040458 | derived:openfda.application_number |
| application applno | ANDA | 040442 | derived:openfda.application_number |
| application number | ANDA040442 | openfda.application_number | |
| application number | ANDA040458 | openfda.application_number | |
| brand name | Carbinoxamine Maleate | openfda.brand_name | |
| generic name | CARBINOXAMINE MALEATE | openfda.generic_name | |
| manufacturer name | Genus Lifesciences Inc. | openfda.manufacturer_name | |
| ndc | package | 64950-243-16 | openfda.package_ndc |
| ndc | package | 64950-243-04 | openfda.package_ndc |
| ndc | package | 64950-211-01 | openfda.package_ndc |
| ndc | product | 64950-211 | openfda.product_ndc |
| ndc | product | 64950-243 | openfda.product_ndc |
| ndc11 | package | 64950024304 | derived:openfda.package_ndc |
| ndc11 | package | 64950024316 | derived:openfda.package_ndc |
| ndc11 | package | 64950021101 | derived:openfda.package_ndc |
| rxcui | 1010696 | openfda.rxcui | |
| rxcui | 1012904 | openfda.rxcui | |
| spl id | 12a85f25-d18a-4408-8c66-4e0182287026 | id | |
| spl set id | 9d11b197-cfdc-4b9b-9935-2920ccb6e522 | set_id | |
| unii | 02O55696WH | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS Deaths have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products, therefore, carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS ). Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The most frequent adverse reactions are underlined: Body as a Whole: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat. Cardiovascular: Hypotension, headache, palpitations, tachycardia, extrasystoles. Hematologic: Hemolytic anemia, thrombocytopenia, agranulocytosis. Central Nervous System: Sedation , sleepiness , dizziness , disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions. Gastrointestinal: Epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation. Urogenital: Urinary frequency, difficult urination, urinary retention, early menses. Respiratory: Thickening of bronchial secretions , tightness of chest and wheezing, nasal stuffiness. To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.